Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.37 |
| ▸ | TUBB | P07437 | 3/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347781 | 0.85 | AVPR1A (0.44) | TNKSTNKS2AVPR1ATGFBR1SRD5A1 | |
| SCHEMBL1347704 | 0.85 | TNKS2 (0.38) | TNKSTNKS2AVPR1AMAPK14THRB | |
| SCHEMBL3397440 | 0.83 | TNKS2 (0.43) | APLNRTNKSTNKS2AVPR1A | |
| SCHEMBL3395958 | 0.83 | HSD11B1 (0.36) | TNKSTNKS2AVPR1ATGFBR1 | |
| SCHEMBL12131735 | 0.82 | TUBB4A (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL314997 | 0.80 | TNKS2 (0.37) | APLNRTNKSTNKS2MAPK14THRB | |
| SCHEMBL314998 | 0.80 | TNKS2 (0.37) | APLNRTNKSTNKS2MAPK14THRB | |
| SCHEMBL314996 | 0.80 | TNKS2 (0.37) | APLNRTNKSTNKS2MAPK14THRB | |
| SCHEMBL3400041 | 0.79 | BRD4 (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3226167 | 0.72 | TNKS2 (0.37) | APLNRTNKSTNKS2PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | claimed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | claimed |
| EP-2111403-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent GmbH (DE) | 2009-10-28 | — | — | EP | claimed |
| WO-2008052628-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | disclosed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2008052628-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | TGFBR1, TGFBR2, ACVR1 | TUBB4A 450/4885TUBB 219/4885TUBA3C 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.